Renalytix announces two presentations accepted at National Kidney Foundaton

Renalytix announced that two scientific presentations have been accepted at the upcoming National Kidney Foundation Spring Clinicals Conference taking place in Austin, Texas. The studies entitled the "Impact of KidneyIntelX testing on novel medication prescription in a diverse patient population" and "Diabetic kidney disease epidemiology in US veterans" show the importance of using KidneyIntelX bioprognosis in early stage kidney disease and diabetes patients. National Kidney Foundation Clinical Spring Conference Data Presentations Include: KidneyIntelX was recently introduced into the Wake Forest-Atrium Health System to predict progressive decline in kidney function. In 590 patients with T2D and early stage CKD, despite similar eGFR, UACR and HbA1c in the Black vs. non-Black populations, the proportion of Black patients in the high-risk category was 3x higher than non-Black. The KidneyIntelX risk score identified those patients at highest risk which resulted in appropriately selecting SGLT2-inhibitors for the right patients. These data demonstrate that health care providers can use KidneyIntelX for risk stratification to guide treatment plans and can be implemented in population health initiatives toward prevention of complications and improved healthcare equity. Diabetic kidney disease epidemiology in US veterans: In a patient cohort of more than 685,000 veterans with T2D and CKD, the authors identified a gap in current standard of care in which patients with early stage DKD may be left underdiagnosed or undetected, since the majority of patients were first identified with CKD at Stage 3a or 3b. These findings demonstrate that T2D and CKD in veteran populations may progress rapidly due to a higher prevalence of comorbidities in the veteran population. This study demonstrates that the Renalytix KidneyIntelX solution as a risk assessment tool for early-stage CKD is well aligned with established Veteran’s Health Administration care guidelines and the 2020 Directive 1053 recommending a validated risk prediction model to support clinical decision making in the management of patients with CKD.